SMS Pharmaceuticals' Q2 FY 2026-27 Quarterly Results
- 05 Nov 2026
Result Summary
- SMS Pharmaceuticals Ltd reported a 52.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 30.2%.
- Its expenses for the quarter were up by 45.8% QoQ and 26.1% YoY.
- The net profit increased 90.6% QoQ and increased 57.4% YoY.
- The earnings per share (EPS) of SMS Pharmaceuticals Ltd stood at 4.26 during Q2 FY 2026-27.
Financial Statments for Q2 FY 2026-27
(₹ crores) | Q2FY27 | Q1FY27 | Q2FY26 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 317.43 | 208.71 | 243.86 | 52.1% | 30.2% |
Total Expenses | 264.61 | 181.50 | 209.82 | 45.8% | 26.1% |
Profit Before Tax | 52.82 | 27.20 | 34.04 | 94.2% | 55.2% |
Tax | 13.25 | 7.00 | 8.91 | 89.3% | 48.7% |
Profit After Tax | 39.85 | 20.91 | 25.31 | 90.6% | 57.4% |
Earnings Per Share | 4.26 | 2.23 | 2.84 | 91.0% | 50.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
SMS Pharmaceuticals Ltd is a prominent Indian pharmaceutical company primarily engaged in the development, manufacture, and sale of active pharmaceutical ingredients (APIs). The company operates within the pharmaceutical industry, which is known for its rigorous regulatory environment and the constant need for innovation due to evolving healthcare requirements. However, specific recent major developments or changes in the company's strategic direction are not available in the provided data. SMS Pharmaceuticals Ltd is recognized for its diversified product portfolio, catering to both domestic and international markets, with a focus on quality and compliance standards.
Revenue
During Q2FY27, SMS Pharmaceuticals Ltd reported a total income of ₹317.43 crores, which represents a significant increase from ₹208.71 crores in Q1FY27. This quarter-over-quarter (QoQ) growth of 52.1% is substantial. Additionally, the year-over-year (YoY) rise from Q2FY26's ₹243.86 crores to the current figure indicates a 30.2% increase. Such growth in total income suggests a robust performance over both the quarterly and annual periods. As a pharmaceutical company, revenue streams are likely bolstered by a mix of product sales, potentially including both existing and newly developed APIs.
Profitability
The profitability metrics for SMS Pharmaceuticals Ltd demonstrate a noteworthy upward trend. In Q2FY27, the profit before tax was ₹52.82 crores, up from ₹27.20 crores in Q1FY27, reflecting a QoQ increase of 94.2%. When compared to the previous year's Q2FY26 profit before tax of ₹34.04 crores, the YoY growth is 55.2%. Similarly, profit after tax in Q2FY27 was ₹39.85 crores, marking a 90.6% QoQ increase from ₹20.91 crores in Q1FY27, and a 57.4% YoY increase from ₹25.31 crores in Q2FY26. These metrics indicate strong profitability improvements. The earnings per share (EPS) followed this trend, rising to ₹4.26 in Q2FY27, compared to ₹2.23 in Q1FY27 and ₹2.84 in Q2FY26, representing 91.0% QoQ and 50.0% YoY growth.
Operating Metrics
Total expenses in Q2FY27 were reported at ₹264.61 crores, showing a 45.8% QoQ rise from ₹181.50 crores in Q1FY27, and a 26.1% YoY increase from ₹209.82 crores in Q2FY26. This increase in expenses aligns with the overall rise in income, suggesting operational scaling. The tax expense increased to ₹13.25 crores in Q2FY27 from ₹7.00 crores in Q1FY27 and ₹8.91 crores in Q2FY26, reflecting 89.3% QoQ and 48.7% YoY growth. While the financial data provided does not include detailed information on liquidity or leverage ratios, the significant growth in income and profit metrics suggests an operational expansion phase.
FAQs
SMS Pharmaceuticals Ltd announced its Q2 FY 2026-27 results on 5 November, 2026.
SMS Pharmaceuticals Ltd quarterly results refer to the company’s financial performance over a three-month period, including key metrics like revenue, net profit, earnings per share (EPS), and margin performance.
Key highlights of SMS Pharmaceuticals Ltd Q2 FY 2026-27 results include:
- Revenue: ₹317.43 crore
- Net Profit: ₹39.85 crore
- EBITDA: ₹68.99 crore
- Year-over-Year Growth: 30.2%
- Quarter-over-Quarter Growth: 52.1%
SMS Pharmaceuticals Ltd reported a net profit of ₹39.85 crore in Q2 FY 2026-27, reflecting a 57.4% year-over-year growth.
SMS Pharmaceuticals Ltd posted a revenue of ₹317.43 crore in Q2 FY 2026-27.